LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Patients must have adequate organ and marrow function as defined below: ANC ≥1,000/mcL, unless if neutropenia is due to underlying CLL bone marrow disease. Platelets ≥ 50,000/ µL unless if thrombocytopenia is due to underlying CLL bone marrow disease then platelets of ≥20,000 is acceptable. Total bilirubin ≤1.5 x ULN (excepting Gilbert's syndrome). AST and ALT ≤2.5 × ULN. Estimated glomerular filtration rate ≥ 30 mL/min. Patient has significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 180 days prior to the first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or left ventricular ejection fraction ≤ 40%.